Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Feb 10

PMID 38338698

Authors

Carlos Rodriguez-Medina

Ruth Stuckey

Cristina Bilbao-Sieyro

Maria Teresa Gomez-Casares

Affiliations

Soon will be listed here.

Abstract

Recent progress in the use of massive sequencing technologies has greatly enhanced our understanding of acute myeloid leukemia (AML) pathology. This knowledge has in turn driven the development of targeted therapies, such as venetoclax, a BCL-2 inhibitor approved for use in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed adult patients with AML who are not eligible for intensive chemotherapy. However, a significant number of AML patients still face the challenge of disease relapse. In this review, we will explore biomarkers that may predict disease progression in patients receiving venetoclax-based therapy, considering both clinical factors and genetic changes. Despite the many advances, we conclude that the identification of molecular profiles for AML patients who will respond optimally to venetoclax therapy remains an unmet clinical need.

Citing Articles

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.

Niscola P, Gianfelici V, Catalano G, Giovannini M, Mazzone C, Noguera N Curr Oncol. 2024; 31(11):6632-6658.

PMID: 39590121 PMC: 11592437. DOI: 10.3390/curroncol31110490.

References

Burnett A, Wetzler M, Lowenberg B . Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011; 29(5):487-94. DOI: 10.1200/JCO.2010.30.1820. View

Koschade S, Stratmann J, Finkelmeier F, Wagner S, Chromik J, Steffen B . Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations. Ann Hematol. 2022; 101(8):1703-1710. PMC: 9279263. DOI: 10.1007/s00277-022-04862-3. View

Pattingre S, Tassa A, Qu X, Garuti R, Liang X, Mizushima N . Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005; 122(6):927-39. DOI: 10.1016/j.cell.2005.07.002. View

Khalsa J, Cha J, Utro F, Naeem A, Murali I, Kuang Y . Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples. Blood. 2023; 142(5):421-433. PMC: 10447490. DOI: 10.1182/blood.2022016600. View

Arber D, Orazi A, Hasserjian R, Borowitz M, Calvo K, Kvasnicka H . International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228. PMC: 9479031. DOI: 10.1182/blood.2022015850. View

Grob T, Al Hinai A, Sanders M, Kavelaars F, Rijken M, Gradowska P . Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022; 139(15):2347-2354. PMC: 11022827. DOI: 10.1182/blood.2021014472. View

Pan R, Hogdal L, Benito J, Bucci D, Han L, Borthakur G . Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2013; 4(3):362-75. PMC: 3975047. DOI: 10.1158/2159-8290.CD-13-0609. View

Lachowiez C, Reville P, Kantarjian H, Jabbour E, Borthakur G, Daver N . Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022; 97(11):1443-1452. DOI: 10.1002/ajh.26694. View

Sillar J, Enjeti A . Targeting Apoptotic Pathways in Acute Myeloid Leukaemia. Cancers (Basel). 2019; 11(11). PMC: 6895902. DOI: 10.3390/cancers11111660. View

10.

Grimwade D, Ivey A, Huntly B . Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2015; 127(1):29-41. PMC: 4705608. DOI: 10.1182/blood-2015-07-604496. View

11.

Chan S, Thomas D, Corces-Zimmerman M, Xavy S, Rastogi S, Hong W . Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015; 21(2):178-84. PMC: 4406275. DOI: 10.1038/nm.3788. View

12.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

13.

Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J . The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022; 12:985363. PMC: 9597512. DOI: 10.3389/fonc.2022.985363. View

14.

McBride A, Houtmann S, Wilde L, Vigil C, Eischen C, Kasner M . The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome. Front Oncol. 2019; 9:192. PMC: 6445951. DOI: 10.3389/fonc.2019.00192. View

15.

Lachowiez C, Loghavi S, Kadia T, Daver N, Borthakur G, Pemmaraju N . Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020; 4(7):1311-1320. PMC: 7160266. DOI: 10.1182/bloodadvances.2019001267. View

16.

Tiong I, Dillon R, Ivey A, Teh T, Nguyen P, Cummings N . Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol. 2020; 192(6):1026-1030. PMC: 8048658. DOI: 10.1111/bjh.16722. View

17.

Herold T, Jurinovic V, Batcha A, Bamopoulos S, Rothenberg-Thurley M, Ksienzyk B . A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. Haematologica. 2017; 103(3):456-465. PMC: 5830382. DOI: 10.3324/haematol.2017.178442. View

18.

Senapati J, Urrutia S, Loghavi S, Short N, Issa G, Maiti A . Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023; 142(19):1647-1657. DOI: 10.1182/blood.2023020649. View

19.

Findley H, Gu L, Yeager A, Zhou M . Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 1997; 89(8):2986-93. View

20.

Russell N, Hunter A, Bradbury D, Zhu Y, KEITH F . Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia. Leuk Lymphoma. 1995; 16(3-4):223-9. DOI: 10.3109/10428199509049761. View